pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-6830 |
Genomic Coordinates | chr5: 132217849 - 132217918 |
Description | Homo sapiens miR-6830 stem-loop |
Comment | None |
RNA Secondary Structure |
Mature miRNA Information | |||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-6830-3p | ||||||||||||||||||||||||
Sequence | 48| UGUCUUUCUUCUCUCCCUUGCAG |70 | ||||||||||||||||||||||||
Evidence | Experimental | ||||||||||||||||||||||||
Experiments | Meta-analysis | ||||||||||||||||||||||||
SNPs in miRNA |
|
||||||||||||||||||||||||
Putative Targets |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | L2HGDH | ||||||||||||||||||||
Synonyms | C14orf160, L2HGA | ||||||||||||||||||||
Description | L-2-hydroxyglutarate dehydrogenase | ||||||||||||||||||||
Transcript | NM_024884 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on L2HGDH | |||||||||||||||||||||
3'UTR of L2HGDH (miRNA target sites are highlighted) |
>L2HGDH|NM_024884|3'UTR 1 ATAATGAAAGGAGCTAGGTATGCACTGTAATCTTCATGTCAGCAACAAGAATGTACTAATTGCATTCTTTAATTTAAAAA 81 ATGGTTTTTAAACTTTAGTTTTTAGGTCAAAGATAACCACTGCATTGTTAAAATGATGTAACATAGAAATAATAATTTTC 161 TACAAAAATTAGCCAGGCATGGTGGCGCATGCCTGTAATCTCAGCTACTCAGGAGGCTGAGGCAGGAGAATCAATTGAAC 241 CGAGCAGACGGAGGTGAGCTGAGAGCTGAGATTGCACCACTGCACTCCAGCCTGGGTGACAGAGCAAGAAAATAATAATA 321 ATAATAATTTTCAAAATGTTAGGCTGGGGGCCGTGGCCAGCACTTTGGGAAGCCAAGGCAGGTAGATTGTAGCCCAGGAG 401 TTTGAGAACAGCCTGGGCAACATGGCAAAACCCTGTTTCTACACAAAGTTAGCTGGGTCTGGTGCCTCTGTAGTTCCAGC 481 TCCTCAGTAGGCTGAGGTGAGAGGATCACTTGAGCCCAGGAGGTCTAGGCTGCAGTGAGCTTATGTTCATGACACTGCAT 561 TCCAGGCTGGATGATAGAGCAAGATCTTGTCTCAAAAAAAAAAAAAAAAAAAAAAAAAATCCAGCCTGGGCAACATAGTG 641 AATGAAACCCCATCTCTACAAAAAATACAAAAATTAGCTGGGCATGATGGTGTGTGCCTGTAGTCCCAGCTACTTGGGGG 721 CTGAGGCAGGAGGATCGCTTGAGCCCGGGAGATCAAGGCTACAGTGAGCTGTGTTCATGCCACTATACCCCAGCCTGGGC 801 AACAAAGTGAGTCCCTGACTCAAAAAATAAAAACAACAACAAAAAATAAATTCCATGCTTATTTACTTTGCGAATAAAGA 881 GGCAAGGTACAGTTTTATCTGTCCGAATCCCTGACTTTTATTTATTTTTTTTTTCAGACGGAGTTTCACTCTTGTTGCCC 961 AGGCTTGAGTGCAATGGTACGATCTTGGCTCACTGCAACCTCTGCCTCCCGGGTTCCAGCGATTCTCTTGCCTCAACCTC 1041 CTGAGTAGCTGGGATTACAGGCGCCCACCACCATGCCTGGCTAATTTTTTGTATTTTTAGTAGAGACGGGGTTTTGCCAT 1121 GTTGGCCAGGCTGGTCTCGAATTCCTGACCTCAGGTGATCCACCTGCCTCAGCCTCCCAAAATGCTGGGATTACAGGTGC 1201 GAGCCATCATGCTCAGCCCTGAATCCCTGACTTTGTTAATGACCTGTCCTTACCAACCATGACCTAGAGAAGATTTGGCT 1281 TTTTAAGAGTTTTGGAGAAAGATGGCATAAAAATAGATTATTTCCTTAAATCAATTTTTTAGCATTACGCTACCTAAGCT 1361 CGTTTGGTCTCTCATAGACAAGAAAATACATTATATTGTAGGTTACATTCTTTTAATTTTGAAGAGTCACAAAACTCACA 1441 TTATTTAGAGCAACAATATTTGTATTTGGAAATTAAAAATTCATGATTTCAAGAAAATACATAAAATTTACATTTTTGAG 1521 TAGTTTGAATAAGTTTCTATCTTAATTATAATATTTGTAGGAAATAACAAAACAAACTCAAAGCCTTTATTATTTCCAGT 1601 CTCTTTGTAACTGATGTGGTATGGTATCATCATGAAATCTAAACAGTGGTACACTGAGTGGTTGTCCTGTTCTTCAATCT 1681 CTGTGGCTGAGAACTGAAATAACTTAGAAGAGACAGATTTTTATGAGAGCAGTTTTAGAATCCTGACACTGATGTATAGA 1761 ACTCCAATTTAAAAAAGTTATTTATCTATTATATCTCTGATCTTTAGTCACACTAAGGCTCTCAAAATGTTGGCCAAGAT 1841 TGGTAATGATTCATACGTACTTGATTTTTCAGGGCTCCTATAAACTTGTATAGGGATATTTTTCCATTTTTGATAAATAT 1921 CTAACTTTGAGGCATTCACTTTTGTAAACCGCGAAAGTGCCTTACATTCACCTCATGAGTATTTTAAGTTGATGCCCAGT 2001 GCTGTGGTATATCCTGTATATATGTGTTTTGTGGTATCTATCGAAATTATTCTTATAATTTAGAAAGTTAGAAAATAGAA 2081 ATTGTAAATGAAAATGTGGCGACCTGACTGCAGAACTTTGAGTACTGAACCACATTTAGGTGAGGCATTTTCATCCATTC 2161 TCTCTGATTTGCTCTCTCAGGATTCATCTTCTACTGTGTATGTCTTCTTTCCTCTTAGCTCTCCAAAGCTGTATGATGGA 2241 TGGGTGAGAAGGATGTGCATTTTGGTTGATAGGAAAAATGTTTCTGTTTTCTTCCTTTTCCCCTCACTTCAAGCATTGAT 2321 GATTACATTGATTGAGCTACCTCATCCATTAATTTGAAAGGCTACACTTCATCAGCTCATGTTTAAGAAGTAGCACATCC 2401 CAGGTAAACAGAGTAGGCCATTATTCAACTCTTAGGATGAGTATATTAAAAGCATTCAGATATCAATGACAGAAGAAACA 2481 AGCCCTAATGTTTCTTTATAACAGCTGATTCCTGCAAGAAATGCAAACACAGGATATTTTTCTGTTCCATTACAAGATTA 2561 CTAAGAGATGGAAAATATTATCATTCTGTATTTTGTCAGTAGTACGATTGCATACATACTAAGTTGTAAACATTGAATTA 2641 CAAAAAATGATTGTCCTAATTGAAGCAGTCCTCAATCCATTTGAGTCTGTACAATACCCTGAAAAGGAAACAACAGGTGC 2721 TGGAGAGGATGTGGAGAAATAGGAACACTTTTACACTGTTGGTGGGACTGTAAACTAGTTCAACCATTGTGGAAGTCAGT 2801 GTGGCGATTCCTCAGGGATCTGGAACTAGAAATACCATTTGACCCAGCCATCCCATTACTGGGTATATACCCAAGGGACT 2881 ATAAATCATGCTGCTATAAAGACACATGCACACGTATGTTTATTGTGGCACTATTCACAATAGTAAAGACTTGGAACCAA 2961 CCCAAATGTCCAACAACGATAGACTGGATTAAGAAAATGTGGCACATATACACCATGGAATACTATGCAGCCATAAAAAA 3041 TGATGAGTTCATGTCCTTTGTAGGGACATGGATGAAATTGGAAATCATCATTCTCAGTAAACTATCGCAAGAACAAAAAA 3121 CCAAACACCGCATGTTCTCACTCATAGATGGGAATTGAACAATGAGAACACATGGACACAGGAAGGGGAACATCACACTC 3201 TGGGGACTGTTGTGGGGTGGGGGGAGGGGGGAGGGATAGCATTAGGAGATATACCTAATGCTAAATGACGAGTTAATGGG 3281 TGCAGCACACCAGCACGGCACATGTATACATATGTAACTAACCTGCACATTGTGCACATGTACCCTAAAACTTAAAGTAT 3361 AATAATAAACAATATATATATATATATATATATAAAATACCCTGAAAAATAAAAATGAAAAATTTGTTGAAAGTGTTTTG 3441 AATATGTAGGTTATTCTGCTTGTAAAACGTTTTATATGTATGTCAATAGGGTTTTTTTGTTTAATACTGATATAATAAAG 3521 TTTTATGTATTTCTGACAGAAGAAATGTATATTAATATTTAAAATATTTTAATGAGCCTTGGTGTTGTAGAGAACATATT 3601 TTTTAGTTCCATAAAAACTTTTATGCAAATAAATTTTTTTATGTGTAAAACATAAACTGTTTGCTTTAGATAGATAGCAG 3681 CCAACCTTTTTAAAAAACTCATTTCTGTGTTAGTATATAATACAAAATGAGGTTGAGTCATTTATATTTTGGGTAAAAAG 3761 TGGAGCATTTTAGATTTTAACTTCAGAGTGTTTGTGAGGAACTCTTGATGTACCAGCAAGTATATTTTTGGTGTTTCATG 3841 TTACGTAGCTTAACTCTTTTATCCATACATATATGTGTATATCAAAGTCCTTCCCTTGATCCTCTCAGCATTAGCACTGT 3921 TTGGGGAGTTGCCTTTACTGTTGGCAGAATTCCACTTTCCCTGAGGCCATTTGGAAATCTACCTAGTAGCCTGTGGGATA 4001 ACCTTAACTCTTAGAACTTTCTTCAAAGGATGGTGGTGAGAATGGGGTATACTGCCAGGCCCTGGCCTACGGGAGTTTGT 4081 AGGGCCTACTTTTGGAGGCAATCCAACCCTGATGGCTGTACCTATGAGCTATCCCTGTAAACACAGGAGACATGGTGTCT 4161 ATATTGTTTAAGGACTGGCTCTGCCCTCCTGGGCCCTTAATCTGTGTCTAGACTTCTTGGTCAGAGGTTTCCTCATCTTT 4241 CTGCGCATACACTATTATCTAAAGATCTTGTAAACATTTTTGAGTTGTAATCGTAAAGTCAGTTTCTAAGCTTTTCTAAC 4321 ACACTCAAAGGGAGTTTTTGAAATCTCTTCATCAGGGCTTAAGGTAGAAGGACAGGGTGAAATGGTTGGGAAAGCAAAAG 4401 CTGCCTCGAGATGTTTTCAAATAGTTTGTACTCATTAAATAGCTTAAGAATGGAAATAAACCCTGAAGCCCTGAAGGGAA 4481 GAACAGTGTTGATACCAACCAACTCTACTTTTCTGGCCTCAAATCCTAGAAAGTATTGTGGGTTTGTTGTTGTTGTTGAT 4561 GTTGTTAATTGCTTGTATTTTCTGCTTATGGGAAGGATCTCACATTAAAGTTATCTTATTTTAAAAAAAAAAAAAAAAAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | HEK293 |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in GSM545212. RNA binding protein: AGO1. Condition:Control
PAR-CLIP data was present in GSM545214. RNA binding protein: AGO3. Condition:Control
PAR-CLIP data was present in GSM545216. RNA binding protein: AGO2. Condition:miR-124 transfection
... - Hafner M; Landthaler M; Burger L; Khorshid et al., 2010, Cell. |
Article |
- Hafner M; Landthaler M; Burger L; Khorshid et al. - Cell, 2010
RNA transcripts are subject to posttranscriptional gene regulation involving hundreds of RNA-binding proteins (RBPs) and microRNA-containing ribonucleoprotein complexes (miRNPs) expressed in a cell-type dependent fashion. We developed a cell-based crosslinking approach to determine at high resolution and transcriptome-wide the binding sites of cellular RBPs and miRNPs. The crosslinked sites are revealed by thymidine to cytidine transitions in the cDNAs prepared from immunopurified RNPs of 4-thiouridine-treated cells. We determined the binding sites and regulatory consequences for several intensely studied RBPs and miRNPs, including PUM2, QKI, IGF2BP1-3, AGO/EIF2C1-4 and TNRC6A-C. Our study revealed that these factors bind thousands of sites containing defined sequence motifs and have distinct preferences for exonic versus intronic or coding versus untranslated transcript regions. The precise mapping of binding sites across the transcriptome will be critical to the interpretation of the rapidly emerging data on genetic variation between individuals and how these variations contribute to complex genetic diseases.
LinkOut: [PMID: 20371350]
|
Experimental Support 2 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | HEK293 |
Disease | 79944.0 |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
"PAR-CLIP data was present in GSM714645. RNA binding protein: AGO2. Condition:completeT1
... - Kishore S; Jaskiewicz L; Burger L; Hausser et al., 2011, Nature methods. |
Article |
- Kishore S; Jaskiewicz L; Burger L; Hausser et al. - Nature methods, 2011
Cross-linking and immunoprecipitation (CLIP) is increasingly used to map transcriptome-wide binding sites of RNA-binding proteins. We developed a method for CLIP data analysis, and applied it to compare CLIP with photoactivatable ribonucleoside-enhanced CLIP (PAR-CLIP) and to uncover how differences in cross-linking and ribonuclease digestion affect the identified sites. We found only small differences in accuracies of these methods in identifying binding sites of HuR, which binds low-complexity sequences, and Argonaute 2, which has a complex binding specificity. We found that cross-link-induced mutations led to single-nucleotide resolution for both PAR-CLIP and CLIP. Our results confirm the expectation from original CLIP publications that RNA-binding proteins do not protect their binding sites sufficiently under the denaturing conditions used during the CLIP procedure, and we show that extensive digestion with sequence-specific RNases strongly biases the recovered binding sites. This bias can be substantially reduced by milder nuclease digestion conditions.
LinkOut: [PMID: 21572407]
|
Experimental Support 3 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | HEK293 |
Disease | 79944.0 |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
"PAR-CLIP data was present in GSM1065667. RNA binding protein: AGO1. Condition:4-thiouridine
... - Memczak S; Jens M; Elefsinioti A; Torti F; et al., 2013, Nature. |
Article |
- Memczak S; Jens M; Elefsinioti A; Torti F; et al. - Nature, 2013
Circular RNAs (circRNAs) in animals are an enigmatic class of RNA with unknown function. To explore circRNAs systematically, we sequenced and computationally analysed human, mouse and nematode RNA. We detected thousands of well-expressed, stable circRNAs, often showing tissue/developmental-stage-specific expression. Sequence analysis indicated important regulatory functions for circRNAs. We found that a human circRNA, antisense to the cerebellar degeneration-related protein 1 transcript (CDR1as), is densely bound by microRNA (miRNA) effector complexes and harbours 63 conserved binding sites for the ancient miRNA miR-7. Further analyses indicated that CDR1as functions to bind miR-7 in neuronal tissues. Human CDR1as expression in zebrafish impaired midbrain development, similar to knocking down miR-7, suggesting that CDR1as is a miRNA antagonist with a miRNA-binding capacity ten times higher than any other known transcript. Together, our data provide evidence that circRNAs form a large class of post-transcriptional regulators. Numerous circRNAs form by head-to-tail splicing of exons, suggesting previously unrecognized regulatory potential of coding sequences.
LinkOut: [PMID: 23446348]
|
Experimental Support 4 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | MCF7 |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in SRR1045082. RNA binding protein: AGO2. Condition:Untreated
... - Farazi TA; Ten Hoeve JJ; Brown M; et al., 2014, Genome biology. |
Article |
- Farazi TA; Ten Hoeve JJ; Brown M; et al. - Genome biology, 2014
BACKGROUND: Various microRNAs (miRNAs) are up- or downregulated in tumors. However, the repression of cognate miRNA targets responsible for the phenotypic effects of this dysregulation in patients remains largely unexplored. To define miRNA targets and associated pathways, together with their relationship to outcome in breast cancer, we integrated patient-paired miRNA-mRNA expression data with a set of validated miRNA targets and pathway inference. RESULTS: To generate a biochemically-validated set of miRNA-binding sites, we performed argonaute-2 photoactivatable-ribonucleoside-enhanced crosslinking and immunoprecipitation (AGO2-PAR-CLIP) in MCF7 cells. We then defined putative miRNA-target interactions using a computational model, which ranked and selected additional TargetScan-predicted interactions based on features of our AGO2-PAR-CLIP binding-site data. We subselected modeled interactions according to the abundance of their constituent miRNA and mRNA transcripts in tumors, and we took advantage of the variability of miRNA expression within molecular subtypes to detect miRNA repression. Interestingly, our data suggest that miRNA families control subtype-specific pathways; for example, miR-17, miR-19a, miR-25, and miR-200b show high miRNA regulatory activity in the triple-negative, basal-like subtype, whereas miR-22 and miR-24 do so in the HER2 subtype. An independent dataset validated our findings for miR-17 and miR-25, and showed a correlation between the expression levels of miR-182 targets and overall patient survival. Pathway analysis associated miR-17, miR-19a, and miR-200b with leukocyte transendothelial migration. CONCLUSIONS: We combined PAR-CLIP data with patient expression data to predict regulatory miRNAs, revealing potential therapeutic targets and prognostic markers in breast cancer.
LinkOut: [PMID: 24398324]
|
CLIP-seq Support 1 for dataset GSM545212 | |
---|---|
Method / RBP | PAR-CLIP / AGO1 |
Cell line / Condition | HEK293 / Control |
Location of target site | ENST00000267436.4 | 3UTR | ACUAUAAAUCAUGCUGCUAUAAA |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 20371350 / GSE21578 |
CLIP-seq Viewer | Link |
CLIP-seq Support 2 for dataset GSM545214 | |
---|---|
Method / RBP | PAR-CLIP / AGO3 |
Cell line / Condition | HEK293 / Control |
Location of target site | ENST00000267436.4 | 3UTR | ACUAUAAAUCAUGCUGCUAUA |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 20371350 / GSE21578 |
CLIP-seq Viewer | Link |
CLIP-seq Support 3 for dataset GSM545216 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | HEK293 / miR-124 transfection |
Location of target site | ENST00000267436.4 | 3UTR | GACUAUAAAUCAUGCUGCUAUAAAG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 20371350 / GSE21578 |
CLIP-seq Viewer | Link |
CLIP-seq Support 4 for dataset GSM714645 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | HEK293 / completeT1, repB |
Location of target site | ENST00000267436.4 | 3UTR | ACUAUAAAUCAUGCUGCUAUAAAG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 21572407 / GSE28865 |
CLIP-seq Viewer | Link |
CLIP-seq Support 5 for dataset GSM1065667 | |
---|---|
Method / RBP | PAR-CLIP / AGO1 |
Cell line / Condition | HEK293 / 4-thiouridine, ML_MM_6 |
Location of target site | ENST00000267436.4 | 3UTR | GACUAUAAAUCAUGCUGCUAUAAAG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 23446348 / GSE43573 |
CLIP-seq Viewer | Link |
CLIP-seq Support 6 for dataset SRR1045082 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | MCF7 / Untreated |
Location of target site | ENST00000267436.4 | 3UTR | ACUAUAAAUCAUGCUGCUAUAAAGA |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 24398324 / SRX388831 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | |||||||
---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | |||||||
---|---|---|---|---|---|---|---|
|
82 hsa-miR-6830-3p Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT081461 | SSBP4 | single stranded DNA binding protein 4 | 2 | 2 | ||||||||
MIRT132029 | IER5 | immediate early response 5 | 2 | 2 | ||||||||
MIRT187279 | DAZAP2 | DAZ associated protein 2 | 2 | 6 | ||||||||
MIRT350303 | TMEM189-UBE2V1 | TMEM189-UBE2V1 readthrough | 2 | 8 | ||||||||
MIRT350307 | UBE2V1 | ubiquitin conjugating enzyme E2 V1 | 2 | 8 | ||||||||
MIRT372105 | EIF3H | eukaryotic translation initiation factor 3 subunit H | 2 | 2 | ||||||||
MIRT408159 | DCK | deoxycytidine kinase | 2 | 4 | ||||||||
MIRT442623 | LOX | lysyl oxidase | 2 | 2 | ||||||||
MIRT442952 | ASXL2 | additional sex combs like 2, transcriptional regulator | 2 | 2 | ||||||||
MIRT469401 | REL | REL proto-oncogene, NF-kB subunit | 2 | 6 | ||||||||
MIRT476631 | G2E3 | G2/M-phase specific E3 ubiquitin protein ligase | 2 | 2 | ||||||||
MIRT485039 | TMEM189 | transmembrane protein 189 | 2 | 8 | ||||||||
MIRT485133 | RASSF8 | Ras association domain family member 8 | 2 | 6 | ||||||||
MIRT498963 | ORC4 | origin recognition complex subunit 4 | 2 | 8 | ||||||||
MIRT500082 | L2HGDH | L-2-hydroxyglutarate dehydrogenase | 2 | 8 | ||||||||
MIRT503018 | CAND1 | cullin associated and neddylation dissociated 1 | 2 | 2 | ||||||||
MIRT503374 | SCAMP1 | secretory carrier membrane protein 1 | 2 | 2 | ||||||||
MIRT504975 | ZNF711 | zinc finger protein 711 | 2 | 2 | ||||||||
MIRT518984 | NNT | nicotinamide nucleotide transhydrogenase | 2 | 4 | ||||||||
MIRT520754 | TFDP1 | transcription factor Dp-1 | 2 | 6 | ||||||||
MIRT526785 | SGCD | sarcoglycan delta | 2 | 2 | ||||||||
MIRT533868 | TBL1XR1 | transducin beta like 1 X-linked receptor 1 | 2 | 2 | ||||||||
MIRT535107 | PMEPA1 | prostate transmembrane protein, androgen induced 1 | 2 | 2 | ||||||||
MIRT538991 | BAG4 | BCL2 associated athanogene 4 | 2 | 2 | ||||||||
MIRT543518 | PRSS21 | protease, serine 21 | 2 | 2 | ||||||||
MIRT543813 | SNX10 | sorting nexin 10 | 2 | 2 | ||||||||
MIRT543825 | GSG1 | germ cell associated 1 | 2 | 2 | ||||||||
MIRT545334 | CCDC83 | coiled-coil domain containing 83 | 2 | 2 | ||||||||
MIRT545669 | DECR1 | 2,4-dienoyl-CoA reductase 1 | 2 | 2 | ||||||||
MIRT547798 | KAT7 | lysine acetyltransferase 7 | 2 | 2 | ||||||||
MIRT548068 | GIGYF1 | GRB10 interacting GYF protein 1 | 2 | 2 | ||||||||
MIRT549577 | ZNF850 | zinc finger protein 850 | 2 | 2 | ||||||||
MIRT550753 | ENTPD1 | ectonucleoside triphosphate diphosphohydrolase 1 | 2 | 2 | ||||||||
MIRT550808 | FAM229B | family with sequence similarity 229 member B | 2 | 2 | ||||||||
MIRT551457 | CARKD | NAD(P)HX dehydratase | 2 | 2 | ||||||||
MIRT551852 | RPS3 | ribosomal protein S3 | 2 | 2 | ||||||||
MIRT554218 | SLC30A1 | solute carrier family 30 member 1 | 2 | 2 | ||||||||
MIRT556588 | LEPROT | leptin receptor overlapping transcript | 2 | 2 | ||||||||
MIRT557344 | HDGF | heparin binding growth factor | 2 | 4 | ||||||||
MIRT571945 | LARP1 | La ribonucleoprotein domain family member 1 | 2 | 2 | ||||||||
MIRT574374 | YY1 | YY1 transcription factor | 2 | 2 | ||||||||
MIRT611142 | CRISP1 | cysteine rich secretory protein 1 | 2 | 4 | ||||||||
MIRT611799 | FCRL4 | Fc receptor like 4 | 2 | 2 | ||||||||
MIRT612834 | KCNN3 | potassium calcium-activated channel subfamily N member 3 | 2 | 2 | ||||||||
MIRT617257 | GLIPR1L2 | GLI pathogenesis related 1 like 2 | 2 | 2 | ||||||||
MIRT619781 | NRIP2 | nuclear receptor interacting protein 2 | 2 | 2 | ||||||||
MIRT620440 | SEMA3E | semaphorin 3E | 2 | 2 | ||||||||
MIRT621725 | TNR | tenascin R | 2 | 2 | ||||||||
MIRT622905 | PCDH17 | protocadherin 17 | 2 | 2 | ||||||||
MIRT623428 | KLF6 | Kruppel like factor 6 | 2 | 2 | ||||||||
MIRT627856 | PITPNM3 | PITPNM family member 3 | 2 | 2 | ||||||||
MIRT633894 | FGF10 | fibroblast growth factor 10 | 2 | 2 | ||||||||
MIRT636257 | SEC24D | SEC24 homolog D, COPII coat complex component | 2 | 2 | ||||||||
MIRT640654 | FRY | FRY microtubule binding protein | 2 | 2 | ||||||||
MIRT640857 | TSHZ2 | teashirt zinc finger homeobox 2 | 2 | 4 | ||||||||
MIRT641220 | LRCH1 | leucine rich repeats and calponin homology domain containing 1 | 2 | 2 | ||||||||
MIRT642526 | ANKRD9 | ankyrin repeat domain 9 | 2 | 2 | ||||||||
MIRT646011 | TNFAIP8L2 | TNF alpha induced protein 8 like 2 | 2 | 2 | ||||||||
MIRT653317 | SMOC1 | SPARC related modular calcium binding 1 | 2 | 2 | ||||||||
MIRT657940 | GATM | glycine amidinotransferase | 2 | 2 | ||||||||
MIRT658291 | FAM83F | family with sequence similarity 83 member F | 2 | 2 | ||||||||
MIRT660607 | ANTXR2 | anthrax toxin receptor 2 | 2 | 2 | ||||||||
MIRT664675 | LMBR1L | limb development membrane protein 1 like | 2 | 2 | ||||||||
MIRT664889 | PRRG4 | proline rich and Gla domain 4 | 2 | 2 | ||||||||
MIRT666972 | PHF20L1 | PHD finger protein 20 like 1 | 2 | 2 | ||||||||
MIRT669128 | CD200 | CD200 molecule | 2 | 2 | ||||||||
MIRT673267 | RUNDC1 | RUN domain containing 1 | 2 | 2 | ||||||||
MIRT704609 | CLN8 | CLN8, transmembrane ER and ERGIC protein | 2 | 2 | ||||||||
MIRT709404 | TADA2A | transcriptional adaptor 2A | 2 | 2 | ||||||||
MIRT710963 | CMKLR1 | chemerin chemokine-like receptor 1 | 2 | 2 | ||||||||
MIRT711745 | DTX1 | deltex E3 ubiquitin ligase 1 | 2 | 2 | ||||||||
MIRT715009 | CYP1B1 | cytochrome P450 family 1 subfamily B member 1 | 2 | 2 | ||||||||
MIRT715467 | NEGR1 | neuronal growth regulator 1 | 2 | 2 | ||||||||
MIRT715737 | CD226 | CD226 molecule | 2 | 2 | ||||||||
MIRT716526 | KSR2 | kinase suppressor of ras 2 | 2 | 2 | ||||||||
MIRT718311 | TMPRSS11B | transmembrane protease, serine 11B | 2 | 2 | ||||||||
MIRT719006 | TMEM184C | transmembrane protein 184C | 2 | 2 | ||||||||
MIRT719319 | STAC | SH3 and cysteine rich domain | 2 | 2 | ||||||||
MIRT722092 | SUSD1 | sushi domain containing 1 | 2 | 2 | ||||||||
MIRT723198 | TNRC6C | trinucleotide repeat containing 6C | 2 | 2 | ||||||||
MIRT723239 | BTLA | B and T lymphocyte associated | 2 | 2 | ||||||||
MIRT724850 | IGFBP5 | insulin like growth factor binding protein 5 | 2 | 2 |